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Introduction
Endothelin 1 (ET1, see table 1 for gene and protein abbreviations) signaling has been 
recognized as a driver of osteoblastic metastasis for more than a decade and recent work 
points to its having a broader role in bone biology. This review will first outline the ET 
signaling pathway and ET metabolism. It will next summarize the role of ET1 signaling in 
craniofacial development. Then, it will discuss observations relating ET signaling to 
osteoblastic and other osteosclerotic processes in cancer. Finally, it will describe recent work 
in our laboratory that points to endothelin signaling as the role of as an upstream mediator of 
WNT signaling, promoting bone matrix synthesis and mineralization. It will conclude with a 
statement of some remaining gaps in knowledge and proposals for future research. These 
will be informed by insights gained from study of ET signaling in the development and 
physiology of the cardiovascular system.
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Overview of the ET Signaling Pathway
The ET system includes 3 small peptide hormones1-3, ET1, ET2, and ET3, 2 G-protein 
coupled receptors4,5, EDNRA and EDNRB, and 2 specific converting enzymes6,7, ECE1 and 
ECE2. The ETs are synthesized as prepropeptides that are first processed to biologically 
inactive, 37-41 amino acid propeptides, commonly known as “big ET’s,” by furin-like 
proteases prior to secretion8,9. Following secretion, the big ETs must be converted to their 
active forms by proteolytic cleavage in the extracellular space. ECE1 and ECE2, which have 
different pH optima (neutral pH optimal for ECE1, acidi pH optimal for ECE2), catalyze ET 
activation by cleaving the big ET’s to 21 amino acid active ETs. In addition, big ET’s can be 
converted by a variety of other proteases (figures 1 and 2)10-12.
The ET system was discovered in arteries, and it has since been shown that various elements 
of the system are expressed in a wide variety of tissues, but expression is not ubiquitous. 
Immortalized osteoblasts in culture express ET1, EDNRA, and ECE1, thus having the 
capacity for autocrine ET signaling within the lineage13. Conversely, ET2, ET3, EDNRB 
and ECE2 are either not detected or expressed at very low levels in these cells13.
ET1 Signaling in Development
Knockout mice lacking either ET1 or EDNRA have very similar, lethal phenotypes that 
result from malformations of the craniofacial bones14,15. Mice die shortly after birth due to 
asphyxia, which can be overcome by tracheostomy. They have hypoplastic mandibles, 
homeotic transformation of the mandible to a maxillary morphology16,17. There are multiple 
defects in other facial and basilar skull bones, and the hyoid bones. Together, these defects 
obstruct the airway, leading to the observed lethality. Identical craniofacial defects are 
observed in ECE1 knockout mice18.
In addition to the craniofacial abnormalities, ET1 and EDNRA knockout mice share defects 
of the cardiac outflow tract and great vessels15,19. These defects are not fully penetrant, and 
include tubular hypoplasia of the aortic arch, absent right subclavian artery and 
perimembranous ventricular septal defect. In ECE1 knockout mice, these defects are both 
more severe and more penetrant than in the ET1 and EDNRA knockouts18. Box 1 provides 
further information about ET signaling in cardiovascular physiology.
The common element linking the craniofacial and cardiovascular anomalies is that the 
affected structures are derived from the neural crest. Cranial and cardiac neural crest cells 
migrate early in development and express EDNRA15. It is worth noting that knockouts of 
ET3 and EDNRB, which are also lethal, affect a different population of neural crest 
derivatives. Phenotypes of these mutations include colonic aganglionosis (Hirschsprung’s 
disease) and white spotting20,21. As in the case of EDNRA/ET1, EDNRB/ET3 knockouts 
have very similar phenotypes. ECE1 knockout animals have all the defects characteristic of 
both the EDNRA/ET1 and EDNRB/ET3 knockouts18.
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ET Signaling in Osteoblastic Metastasis
ET signaling occurs in both mammary and prostate glands, and when it is expressed in 
neoplasms arising from those tissues, it promotes osteoblastic metastasis22-26. Osteoblastic 
metastasis is very common in prostate cancer and uncommon in breast cancer. In both cases, 
lesions feature synthesis of sclerotic, woven bone that is mechanically deficient. We recently 
found that ET1 is highly expressed in the setting of osteosclerosis associated with 
myelofibrosis27, with very similar features to those encountered in breast and prostate 
cancer. Promotion of osteogenesis by ET1 signaling is mediated at least in part by 
modulation of WNT signaling. In cultured mouse calvarial osteoblasts, ET1 reduces 
transcription and secretion of DKK1, and concomitantly increases bone formation28. In men 
with metastatic prostate cancer, EDNRA blockade suppressed progression of bone disease as 
measured by bone turnover markers29.
Human breast cancer cells can convert big ET1 to active ET124,30, suggesting the potential 
role of ET1 in bone metastasis in breast cancer. EDNRA blockade reduced osteoblastic 
lesions in mice inoculated with ZR-75-1 human breast cancer cells24. Collectively, these 
results show that ET1 action via EDNRA mediate bone formation in both breast and prostate 
cancer. The bone cells, in turn, secrete factors that can support proliferation of the tumor 
cells, such as IGF1, resulting in a vicious cycle of concurrent bone and tumor growth 
supported by reciprocal paracrine signaling between tumor cells and osteoblasts.
ET Signaling in Bone Physiology
In the course of pursuing our long-standing interest in the genetic basis of bone 
biomechanical performance, we identified Ece1 as a candidate gene for a pleiotropic 
quantitative trait locus (QTL) for bone size, shape, and strength31-35. The QTL increases the 
cross-sectional size and ellipticity of the femoral diaphysis, leading to an increase in the 
whole bone strength as measured by 3-point bending. This constellation of phenotypes 
suggested that the primary process affected by the QTL was bone modeling in response to 
mechanical loading (see box 2). Other investigators had determined that our QTL lies within 
a genomic region that contributes to load-induced bone modeling36, leading us to 
hypothesize that both sets of phenotypes were mediated by the same genes. It is worth 
noting that the mouse QTL corresponds to a confirmed human BMD QTL37.
In subsequent experiments, we found that murine osteoblasts grown in tissue culture engage 
in autocrine ET1 signaling via EDNRA13 (and Johnson et al., unpublished data). They 
express Edn1, Ednra, and Ece1, but not Ednrb. These cells recapitulate maturation of the 
osteoblast lineage when placed in medium supplemented with vitamin C and phosphate, 
forming mineralized nodules after 2 weeks in mineralization medium. Supplementation of 
the medium with big ET1 increases mineralization, which is blocked by pharmacological 
inhibition of either ECE1 or EDNRA, treatment with SOST, or by transfection of siRNA 
targeting Ece1 message. In addition to promoting mineralization, ET1 treatment reduces 
secretion of SOST and DKK1, in spite of increasing transcription of their mRNAs. These 
divergent effects on transcription and protein secretion are mediated in part by miR 126-3p, 
which is increased by ~120-fold via ET signaling, which targets Sost message. The effects 
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of ET1 signaling on mineralization and SOST secretion are mimicked by transfection of a 
miR 126-3p expressing lentivirus, while the effects of ET1 signaling blockade are mimicked 
by transfection of a lentivirus expressing a miR 126-3p antagonist.
MiR 126-3p is a critical molecule in angiogenesis38. MiR 126-3p ablated mice have a high 
rate of embryonic lethality with impaired blood vessel formation, while the surviving mice 
are deficient in the angiogenic response to experimental ischemia39. Important endothelial 
cell targets of miR-126-3p include, but are not limited to, mRNAs encoding a pair of VEGF 
inhibitors, Pik3r2 and Spred1. It is interesting to note that both in osteoblasts and in 
endothelial cells, miR 126-3p acts by releasing repression of critical signaling pathways.
Future Considerations
Current understanding of ET biology is very uneven. The developmental roles of ET 
signaling are relatively well characterized, as is ET signaling within arterial walls. It is also 
clear that ET drives osteoblastic metastasis in breast and prostate cancer, but little is known 
regarding the role of ET signaling in the normal function of each of these glands, or of the 
contribution ET signaling to normal bone physiology. Greater understanding of the ET 
signaling pathway’s role in the normal biology of tissues outside the vasculature is therefore 
of great importance.
It is important to recall that ET1 signaling is essential in development14,15,18,19, and that the 
phenotypes resulting from knockout of Edn1, Ednra, and Ece1 overlap some of those arising 
from mutants affecting WNT signaling. Ablation of Ece1, unlike that of either Edn1 or 
Ednra, leads to significant mid-gestational in utero lethality due to heart failure, reflecting a 
greater severity of cardiac outflow tract abnormalities18. In the chick, ET1 signaling 
mediates essential mechanotransductive signals in Purkinje system development40-43.
However, the situation is more complex. WNT signaling has an unequivocal trophic impact 
on cells already committed to the osteoblast lineage; indeed, canonical WNT signaling has 
been shown by some investigators to inhibit commitment of mesenchymal stem cells to the 
osteoblast lineage44,45. In addition, mice constitutively expressing β-catenin in late stage 
osteoblasts and osteocytes have both increased bone volume and osteomalacia46. These 
findings demonstrate that normal bone mineralization requires down-regulation of canonical 
WNT signaling at late stages of osteoblast maturation, even while elaboration of bone matrix 
by less mature cells is promoted.
Down-regulation of SOST, leading to derepression of the WNT pathway has been 
demonstrated in an in vivo experimental mechanical loading protocol47. It is unknown at this 
point whether ET signaling mediates the SOST response in this setting, thus functioning 
upstream of the WNT pathway in mediating mechanotransduction in bone. Our laboratory’s 
findings that ET1 signaling reduces SOST expression via miR-126-3p provide a mechanistic 
basis for pursuing this line of investigation13 (and Johnson et al., unpublished data). Other 
investigators have identified DKK1 as another WNT-related target of ET1 signaling in 
cancer28, further supporting the idea that ET signaling is upstream of the WNT pathway in 
bone.
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More broadly, little attention has been devoted to identifying common mechanisms of 
mechanotransduction in bones and arteries. Both are tubular organs whose function requires 
adaptation to highly variable mechanical environments. Bone and vascular biology might 
both benefit by further work in this area.
Finally, osteoblastic metastases arise in other tumors in addition to prostate and breast 
cancer. It is worth studying other tumor types to determine whether they share ET1 signaling 
as the underlying mechanism.
BOX 1
Physiological ET Signaling in the Cardiovascular System
The ET system was first discovered in the vasculature and its biology is best understood 
in that setting. ET signaling via EDNRB on endothelial cells causes vasodilation and 
clearance of ETs from the circulation 48-50. In contrast, signaling via both EDNRA and 
EDNRB in smooth muscle cells has potent vasoconstrictive effects 1,51. Endothelial cells 
are the primary source of ET1 and have a high density of EDNRB, so autocrine signaling 
favors vasodilation and hypotensive responses, while paracrine signaling leads to 
hypertensive responses. In experiments we performed using the same mice in which we 
identified Ece1 as a candidate gene for bone biomechanical performance, we found that 
mice harboring a high-expressing Ece1 allele had larger femoral and arterial cross-
sections, greater arterial compliance, and lower BP than mice harboring a low-expressing 
Ece1 allele 52.
Shear stress plays a critical role in vascular remodeling, both in developmental 53 and 
physiological54-56 settings. NO is known to play a central role in mediating vascular 
remodeling in pregnancy and its induction by shear stress is well established57-59. In this 
setting, NO is produced by NOS3 and the Nos3 gene is induced by EDNRB activation in 
endothelial cells49. Insufficient EDNRB function exacerbates inward hypertophic 
vascular remodeling by low flow60. Taken together, these findings suggest that ET 
signaling via EDNRB could contribute to outward remodeling in response to high shear 
stress.
While osteoblasts and endothelial cells express all the genes necessary for autocrine ET1 
signaling, in blood vessels there is a necessary balance between autocrine and paracrine 
ET1 signaling. Paracrine signaling contributes to the greater thickness and higher smooth 
muscle content of arterial v venous walls. Even though arterial and venous identities are 
established prior to the onset of circulation61, mechanical signals reinforce and amplify 
those differences 53. It is presently unknown whether specific mechanical environments 
lead to differential endothelial cell expression of Edn1 and of Ece1. Should this prove to 
be the case, differential regulation of these genes by distinct mechanical environments 
could provide a mechanism by which wall stress and shear stress might lead to distinct 
adaptive responses.
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BOX 2
The Skeletal Mechanostat and the WNT Pathway
The ability of bone to alter its size and shape in response to its habitual mechanical 
environment is well established. Overloading leads to an increase in long bone cross-
sectional size, as was demonstrated in elite racquet sport athletes 62. Conversely, 
underloading, as occurs in spaceflight, prolonged bed rest, or spinal cord injury leads to 
loss of skeletal mass 63-65. The notion that bone mass is physiologically regulated has 
been formalized in the mechanostat model of bone modeling 66,67. Briefly stated, the 
model holds that bone modeling (change in diameter and/or cross-sectional geometry) 
occurs to maintain mechanical strain (fractional change in length) within a narrow 
physiological range. Once such physiological equilibrium is reached, bone size and shape 
remains stable unless disturbed.
Widely accepted experimental interventions to allow study of defined skeletal loading 
conditions in experimental animals have been developed. Ulnar loading coupled with 
dynamic histomorphometry allows the in vivo modeling response to loading to be 
measured, using the contralateral, unloaded limb as a control 12. Tail suspension 68 and 
sciatic neurectomy 69 both allow study of in vivo unloading. These powerful investigative 
tools have been used in genetically engineered mice to identify critical molecules 
mediating mechanotransduction.
The canonical WNT signaling pathway is one of the principal mechanisms by which 
bone responds to its mechanical environment. Recognition of its central role in bone 
biology emerged from the recognition that inactivating and activating mutations of LRP5, 
a WNT co-receptor, caused two rare Mendelian conditions, the osteoporosis 
pseudoglioma syndrome and hereditary high bone mass, respectively 70-72. Mendelian 
high bone mass high bone mass disorders, sclerosteosis and Van Buchem’s disease, arise 
as a consequence of mutations in SOST, the gene encoding the WNT antagonist 
sclerostin 73,74. Overexpression of the WNT inhibitor DKK1 drives bone resorption in 
multiple myeloma75.
While human disease provided the first clues that WNT signaling is critical in bone 
physiology, mechanistic understanding of bone mass regulation has been achieved 
through study of mouse models. Experiments featuring ulnar loading demonstrated that 
loss of function Lrp5 (mouse homolog of LRP5) mutations lead to decreased load-
induced modeling76,77, while mutations that mimic human high bone mass variants 
display increased modeling in response to mechanical loading77-79. These modeling 
responses demonstrate that disruption of the WNT pathway affects physiology as well as 
development.
SOST is a WNT inhibitor and is produced constitutively by mature osteocytes, but its 
expression is decreased in the presence of mechanical loading47. Mice in which Sost (the 
mouse gene encoding SOST) has been knocked out display increased bone mass, 
mimicking the human sclerosteosis phenotype80,81.
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Furthermore, SNPs within or near genes involved in the WNT pathway are associated 
with mass and fractures in humans37,82-85. In the case of LRP5, there is evidence from 
the Framingham cohort that the association with BMD is exercise dependent86. Anti-
SOST antibodies are presently being tested as possible drugs to increase bone mass and 
prevent fracture87,88.
Acknowledgments
This work was supported in part by SPiRe Award #1I21 RX1440 from the United States Department of Veterans 
Affairs Rehabilitation Research and Development Service to Robert D. Blank. In addition, this material is the result 
of work supported with resources and the use of facilities at the Geriatrics Research, Education, and Clinical Center 
at the William S. Middleton Veterans Hospital in Madison, WI. The opinions expressed herein are those of the 
authors, and do not represent the views of the US government.
This work was supported in part by American Heart Association grant 15GRNT25700126 to Robert D. Blank.
References
1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by 
vascular endothelial cells. Nature. 1988; 332(6163):411–415. [PubMed: 2451132] 
2. Yanagisawa M, Inoue A, Ishikawa T, et al. Primary structure, synthesis, and biological activity of rat 
endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A. 1988; 
85(18):6964–6967. [PubMed: 3045827] 
3. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and 
pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 
1989; 86(8):2863–2867. [PubMed: 2649896] 
4. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an 
endothelin receptor. Nature. 1990; 348(6303):730–732. [PubMed: 2175396] 
5. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective 
subtype of the endothelin receptor. Nature. 1990; 348(6303):732–735. [PubMed: 2175397] 
6. Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the 
proteolytic activation of big endothelin-1. Cell. 1994; 78(3):473–485. [PubMed: 8062389] 
7. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-
sensitive metalloprotease with acidic pH optimum. J Biol Chem. 1995; 270(25):15262–15268. 
[PubMed: 7797512] 
8. Denault JB, Claing A, D'Orleans-Juste P, et al. Processing of proendothelin-1 by human furin 
convertase. FEBS letters. 1995; 362(3):276–280. [PubMed: 7729512] 
9. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human 
preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression. The Journal 
of biological chemistry. 1989; 264(25):14954–14959. [PubMed: 2670930] 
10. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big 
endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999; 85(10):906–911. [PubMed: 
10559137] 
11. Wypij DM, Nichols JS, Novak PJ, Stacy DL, Berman J, Wiseman JS. Role of mast cell chymase in 
the extracellular processing of big-endothelin-1 to endothelin-1 in the perfused rat lung. Biochem 
Pharmacol. 1992; 43(4):845–853. [PubMed: 1540238] 
12. Abassi ZA, Tate JE, Golomb E, Keiser HR. Role of neutral endopeptidase in the metabolism of 
endothelin. Hypertension. 1992; 20(1):89–95. [PubMed: 1618556] 
13. Johnson MG, Kristianto J, Yuan B, Konicke K, Blank R. Big endothelin changes the cellular 
miRNA environment in TMOb osteoblasts and increases mineralization. Connect Tissue Res. 
2014; 55(Suppl 1):113–116. [PubMed: 25158193] 
14. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in 
mice deficient in endothelin-1. Nature. 1994; 368(6473):703–710. [PubMed: 8152482] 
Kristianto et al. Page 7
Endocrinol Metab Clin North Am. Author manuscript; available in PMC 2018 March 01.
V
A
 A
uthor M
anuscript
V
A
 A
uthor M
anuscript
V
A
 A
uthor M
anuscript
15. Clouthier DE, Hosoda K, Richardson JA, et al. Cranial and cardiac neural crest defects in 
endothelin-A receptor-deficient mice. Development. 1998; 125(5):813–824. [PubMed: 9449664] 
16. Ozeki H, Kurihara Y, Tonami K, Watatani S, Kurihara H. Endothelin-1 regulates the dorsoventral 
branchial arch patterning in mice. Mech Dev. 2004; 121(4):387–395. [PubMed: 15110048] 
17. Ruest LB, Clouthier DE. Elucidating timing and function of endothelin-A receptor signaling during 
craniofacial development using neural crest cell-specific gene deletion and receptor antagonism. 
Dev Biol. 2009; 328(1):94–108. [PubMed: 19185569] 
18. Yanagisawa H, Yanagisawa M, Kapur RP, et al. Dual genetic pathways of endothelin-mediated 
intercellular signaling revealed by targeted disruption of endothelin converting enzyme-1 gene. 
Development. 1998; 125(5):825–836. [PubMed: 9449665] 
19. Kurihara Y, Kurihara H, Oda H, et al. Aortic arch malformations and ventricular septal defect in 
mice deficient in endothelin-1. J Clin Invest. 1995; 96(1):293–300. [PubMed: 7615798] 
20. Baynash AG, Hosoda K, Giaid A, et al. Interaction of endothelin-3 with endothelin-B receptor is 
essential for development of epidermal melanocytes and enteric neurons. Cell. 1994; 79(7):1277–
1285. [PubMed: 8001160] 
21. Hosoda K, Hammer RE, Richardson JA, et al. Targeted and natural (piebald-lethal) mutations of 
endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell. 
1994; 79(7):1267–1276. [PubMed: 8001159] 
22. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of 
metastatic adenocarcinoma of the prostate. Nature medicine. 1995; 1(9):944–949.
23. Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone 
pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem. 1999; 
45:1240–1247. 8 Pt 1. [PubMed: 10430790] 
24. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of 
osteoblastic bone metastases. Proc Natl Acad Sci U S A. 2003; 100(19):10954–10959. [PubMed: 
12941866] 
25. Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clin 
Orthop Relat Res. 2003; (415 Suppl):S67–74. [PubMed: 14600594] 
26. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer. 
2003; 97(3 Suppl):779–784. [PubMed: 12548575] 
27. Yachoui R, Kristianto J, Sitwala K, Blank RD. Role of Endothelin-1 in a Syndrome of 
Myelofibrosis and Osteosclerosis. J Clin Endocrinol Metab. 2015; 100(11):3971–3974. [PubMed: 
26358171] 
28. Clines GA, Mohammad KS, Bao Y, et al. Dickkopf homolog 1 mediates endothelin-1-stimulated 
new bone formation. Mol Endocrinol. 2007; 21(2):486–498. [PubMed: 17068196] 
29. Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone 
remodeling by the endothelin receptor A antagonist atrasentan. J Urol. 2003; 169(3):1143–1149. 
[PubMed: 12576870] 
30. Patel KV, Sheth HG, Schrey MP. Stimulation or endothelin-1 secretion by human breast cancer 
cells through protein kinase A activation: a possible novel paracrine loop involving breast 
fibroblast-derived prostaglandin E2. Mol Cell Endocrinol. 1997; 126(2):143–151. [PubMed: 
9089652] 
31. Saless N, Litscher SJ, Vanderby R, Demant P, Blank RD. Linkage mapping of principal 
components for femoral biomechanical performance in a reciprocal HCB-8 x HCB-23 intercross. 
Bone. 2011; 48(3):647–653. [PubMed: 20969983] 
32. Saless N, Litscher SJ, Houlihan MJ, et al. Comprehensive skeletal phenotyping and linkage 
mapping in an intercross of recombinant congenic mouse strains HcB-8 and HcB-23. Cells Tissues 
Organs. 2011; 194(2-4):244–248. [PubMed: 21625064] 
33. Saless N, Lopez Franco GE, Litscher S, et al. Linkage mapping of femoral material properties in a 
reciprocal intercross of HcB-8 and HcB-23 recombinant mouse strains. Bone. 2010; 46(5):1251–
1259. [PubMed: 20102754] 
34. Saless N, Litscher SJ, Lopez Franco GE, et al. Quantitative trait loci for biomechanical 
performance and femoral geometry in an intercross of recombinant congenic mice: restriction of 
the Bmd7 candidate interval. FASEB J. 2009; 23(7):2142–2154. [PubMed: 19261723] 
Kristianto et al. Page 8
Endocrinol Metab Clin North Am. Author manuscript; available in PMC 2018 March 01.
V
A
 A
uthor M
anuscript
V
A
 A
uthor M
anuscript
V
A
 A
uthor M
anuscript
35. Kristianto J, Litscher SJ, Johnson MG, et al. Congenic Strains Confirm the Pleiotropic Effect of 
Chromosome 4 QTL on Mouse Femoral Geometry and Biomechanical Performance. PloS one. 
2016; 11(2):e0148571. [PubMed: 26849124] 
36. Robling AG, Li J, Shultz KL, Beamer WG, Turner CH. Evidence for a skeletal mechanosensitivity 
gene on mouse chromosome 4. FASEB J. 2003; 17(2):324–326. [PubMed: 12490544] 
37. Rivadeneira F, Styrkarsdottir U, Estrada K, et al. Twenty bone-mineral-density loci identified by 
large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009; 41(11):1199–
1206. [PubMed: 19801982] 
38. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular 
integrity. Dev Cell. 2008; 15(2):272–284. [PubMed: 18694566] 
39. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs 
vascular integrity and angiogenesis. Dev Cell. 2008; 15(2):261–271. [PubMed: 18694565] 
40. Gourdie RG, Wei Y, Kim D, Klatt SC, Mikawa T. Endothelin-induced conversion of embryonic 
heart muscle cells into impulse-conducting Purkinje fibers. Proc Natl Acad Sci U S A. 1998; 
95(12):6815–6818. [PubMed: 9618495] 
41. Hall CE, Hurtado R, Hewett KW, et al. Hemodynamic-dependent patterning of endothelin 
converting enzyme 1 expression and differentiation of impulse-conducting Purkinje fibers in the 
embryonic heart. Development. 2004; 131(3):581–592. [PubMed: 14711873] 
42. Sedmera D, Harris BS, Grant E, et al. Cardiac expression patterns of endothelin-converting enzyme 
(ECE): implications for conduction system development. Dev Dyn. 
43. Takebayashi-Suzuki K, Yanagisawa M, Gourdie RG, Kanzawa N, Mikawa T. In vivo induction of 
cardiac Purkinje fiber differentiation by coexpression of preproendothelin-1 and endothelin 
converting enzyme-1. Development. 2000; 127(16):3523–3532. [PubMed: 10903177] 
44. Boland GM, Perkins G, Hall DJ, Tuan RS. Wnt 3a promotes proliferation and suppresses 
osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem. 2004; 93(6):
1210–1230. [PubMed: 15486964] 
45. Liu G, Vijayakumar S, Grumolato L, et al. Canonical Wnts function as potent regulators of 
osteogenesis by human mesenchymal stem cells. J Cell Biol. 2009; 185(1):67–75. [PubMed: 
19349579] 
46. Chen S, Feng J, Bao Q, et al. Adverse Effects of Osteocytic Constitutive Activation of ss-Catenin 
on Bone Strength and Bone Growth. J Bone Miner Res. 2015; 30(7):1184–1194. [PubMed: 
25639729] 
47. Robling AG, Niziolek PJ, Baldridge LA, et al. Mechanical stimulation of bone in vivo reduces 
osteocyte expression of Sost/sclerostin. J Biol Chem. 2008; 283(9):5866–5875. [PubMed: 
18089564] 
48. Masaki T, Kimura S, Yanagisawa M, Goto K. Molecular and cellular mechanism of endothelin 
regulation. Implications for vascular function. Circulation. 1991; 84(4):1457–1468. [PubMed: 
1655302] 
49. Tsukahara H, Ende H, Magazine HI, Bahou WF, Goligorsky MS. Molecular and functional 
characterization of the non-isopeptide-selective ETB receptor in endothelial cells. Receptor 
coupling to nitric oxide synthase. The Journal of biological chemistry. 1994; 269(34):21778–
21785. [PubMed: 7520443] 
50. Frangos JA, Eskin SG, McIntire LV, Ives CL. Flow effects on prostacyclin production by cultured 
human endothelial cells. Science. 1985; 227(4693):1477–1479. [PubMed: 3883488] 
51. Sumner MJ, Cannon TR, Mundin JW, White DG, Watts IS. Endothelin ETA and ETB receptors 
mediate vascular smooth muscle contraction. Br J Pharmacol. 
52. Wang Z, Kristianto J, Yen Ooi C, et al. Blood pressure, artery size, and artery compliance parallel 
bone size and strength in mice with differing ece1 expression. Journal of biomechanical 
engineering. 2013; 135(6):61003–61009. [PubMed: 23699715] 
53. Lucitti JL, Jones EA, Huang C, Chen J, Fraser SE, Dickinson ME. Vascular remodeling of the 
mouse yolk sac requires hemodynamic force. Development. 2007; 134(18):3317–3326. [PubMed: 
17720695] 
54. Langille BL, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood 
flow are endothelium-dependent. Science. 1986; 231(4736):405–407. [PubMed: 3941904] 
Kristianto et al. Page 9
Endocrinol Metab Clin North Am. Author manuscript; available in PMC 2018 March 01.
V
A
 A
uthor M
anuscript
V
A
 A
uthor M
anuscript
V
A
 A
uthor M
anuscript
55. Tuttle JL, Nachreiner RD, Bhuller AS, et al. Shear level influences resistance artery remodeling: 
wall dimensions, cell density, and eNOS expression. Am J Physiol Heart Circ Physiol. 2001; 
281(3):H1380–1389. [PubMed: 11514310] 
56. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the 
importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest. 1998; 
101(4):731–736. [PubMed: 9466966] 
57. Li Y, Zheng J, Bird IM, Magness RR. Effects of pulsatile shear stress on nitric oxide production 
and endothelial cell nitric oxide synthase expression by ovine fetoplacental artery endothelial cells. 
Biology of reproduction. 2003; 69(3):1053–1059. [PubMed: 12773424] 
58. Li Y, Zheng J, Bird IM, Magness RR. Effects of pulsatile shear stress on signaling mechanisms 
controlling nitric oxide production, endothelial nitric oxide synthase phosphorylation, and 
expression in ovine fetoplacental artery endothelial cells. Endothelium : journal of endothelial cell 
research. 2005; 12(1-2):21–39. [PubMed: 16036314] 
59. Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. The American journal of 
physiology. 1997; 272:R441–463. 2 Pt 2. [PubMed: 9124465] 
60. Murakoshi N, Miyauchi T, Kakinuma Y, et al. Vascular endothelin-B receptor system in vivo plays 
a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-
knockout mice. Circulation. 2002; 106(15):1991–1998. [PubMed: 12370225] 
61. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between 
embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell. 1998; 93(5):
741–753. [PubMed: 9630219] 
62. Jones HH, Priest JD, Hayes WC, Tichenor CC, Nagel DA. Humeral hypertrophy in response to 
exercise. J Bone Joint Surg Am. 1977; 59(2):204–208. [PubMed: 845205] 
63. Lang T, LeBlanc A, Evans H, Lu Y, Genant H, Yu A. Cortical and trabecular bone mineral loss 
from the spine and hip in long-duration spaceflight. J Bone Miner Res. 2004; 19(6):1006–1012. 
[PubMed: 15125798] 
64. Donaldson CL, Hulley SB, Vogel JM, Hattner RS, Bayers JH, McMillan DE. Effect of prolonged 
bed rest on bone mineral. Metabolism. 1970; 19(12):1071–1084. [PubMed: 4321644] 
65. Griffiths HJ, Zimmerman RE. The use of photon densitometry to evaluate bone mineral in a group 
of patients with spinal cord injury. Paraplegia. 1973; 10(4):279–284. [PubMed: 4697000] 
66. Frost HM. The Utah paradigm of skeletal physiology: an overview of its insights for bone, 
cartilage and collagenous tissue organs. J Bone Miner Metab. 2000; 18(6):305–316. [PubMed: 
11052462] 
67. Frost HM. From Wolff's law to the Utah paradigm: insights about bone physiology and its clinical 
applications. Anat Rec. 2001; 262(4):398–419. [PubMed: 11275971] 
68. Morey-Holton ER, Globus RK. Hindlimb unloading of growing rats: a model for predicting 
skeletal changes during space flight. Bone. 1998; 22(5 Suppl):83S–88S. [PubMed: 9600759] 
69. Hert J, Sklenska A, Liskova M. Reaction of bone to mechanical stimuli. 5. Effect of intermittent 
stress on the rabbit tibia after resection of the peripheral nerves. Folia Morphol (Praha). 1971; 
19(4):378–387. [PubMed: 5110978] 
70. Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related 
protein 5. N Engl J Med. 2002; 346(20):1513–1521. [PubMed: 12015390] 
71. Gong Y, Slee RB, Fukai N, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and 
eye development. Cell. 2001; 107(4):513–523. [PubMed: 11719191] 
72. Little RD, Carulli JP, Del Mastro RG, et al. A mutation in the LDL receptor-related protein 5 gene 
results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002; 70(1):11–19. 
[PubMed: 11741193] 
73. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the 
SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001; 68(3):577–
589. [PubMed: 11179006] 
74. Balemans W, Patel N, Ebeling M, et al. Identification of a 52 kb deletion downstream of the SOST 
gene in patients with van Buchem disease. J Med Genet. 2002; 39(2):91–97. [PubMed: 11836356] 
Kristianto et al. Page 10
Endocrinol Metab Clin North Am. Author manuscript; available in PMC 2018 March 01.
V
A
 A
uthor M
anuscript
V
A
 A
uthor M
anuscript
V
A
 A
uthor M
anuscript
75. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the 
development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003; 349(26):2483–2494. 
[PubMed: 14695408] 
76. Sawakami K, Robling AG, Ai M, et al. The Wnt co-receptor LRP5 is essential for skeletal 
mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J 
Biol Chem. 2006; 281(33):23698–23711. [PubMed: 16790443] 
77. Cui Y, Niziolek PJ, MacDonald BT, et al. Lrp5 functions in bone to regulate bone mass. Nature 
medicine. 2011; 17(6):684–691.
78. Akhter MP, Wells DJ, Short SJ, et al. Bone biomechanical properties in LRP5 mutant mice. Bone. 
2004; 35(1):162–169. [PubMed: 15207752] 
79. Robinson JA, Chatterjee-Kishore M, Yaworsky PJ, et al. Wnt/beta-catenin signaling is a normal 
physiological response to mechanical loading in bone. J Biol Chem. 2006; 281(42):31720–31728. 
[PubMed: 16908522] 
80. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in 
increased bone formation and bone strength. J Bone Miner Res. 2008; 23(6):860–869. [PubMed: 
18269310] 
81. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the 
deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001; 10(5):537–543. [PubMed: 
11181578] 
82. Sims AM, Shephard N, Carter K, et al. Genetic analyses in a sample of individuals with high or 
low BMD shows association with multiple Wnt pathway genes. J Bone Miner Res. 2008; 23(4):
499–506. [PubMed: 18021006] 
83. Richards JB, Rivadeneira F, Inouye M, et al. Bone mineral density, osteoporosis, and osteoporotic 
fractures: a genome-wide association study. Lancet. 2008; 371(9623):1505–1512. [PubMed: 
18455228] 
84. Uitterlinden AG, Arp PP, Paeper BW, et al. Polymorphisms in the sclerosteosis/van Buchem 
disease gene (SOST) region are associated with bone-mineral density in elderly whites. Am J Hum 
Genet. 2004; 75(6):1032–1045. [PubMed: 15514891] 
85. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone 
mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012; 44(5):
491–501. [PubMed: 22504420] 
86. Kiel DP, Ferrari SL, Cupples LA, et al. Genetic variation at the low-density lipoprotein receptor-
related protein 5 (LRP5) locus modulates Wnt signaling and the relationship of physical activity 
with bone mineral density in men. Bone. 2007; 40(3):587–596. [PubMed: 17137849] 
87. McClung MR, Grauer A. Romosozumab in postmenopausal women with osteopenia. N Engl J 
Med. 2014; 370(17):1664–1665.
88. Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of 
blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J 
Bone Miner Res. 2015; 30(2):216–224. [PubMed: 25196993] 
Kristianto et al. Page 11
Endocrinol Metab Clin North Am. Author manuscript; available in PMC 2018 March 01.
V
A
 A
uthor M
anuscript
V
A
 A
uthor M
anuscript
V
A
 A
uthor M
anuscript
Key Points
• The endothelin system includes 3 small peptide hormones that are secreted as 
inactive precursors, a pair of G-protein coupled receptors, and a pair of 
membrane bound, extracellular converting enzymes.
• Endothelin 1/endothelin receptor A signaling is essential for the development 
of the craniofacial skeleton. Knockouts of the Edn1, Ednra, and Ece1 genes 
have lethal phenotypes.
• Endothelin signaling is osteogenic in the setting of prostate and breast cancer.
• Genetic evidence points to allelic variation of Ece1 as a mediator of bone 
biomechanical performance.
• In vitro experiments indicate that ET signaling derepresses WNT signaling, 
and thus may function upstream of WNT in mediating mechanical 
homeostasis of skeletal mass.
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Synopsis
The endothelin (ET) system includes 3 small peptide hormones and a pair of G-protein 
coupled receptors. All 3 ETs are secreted as biologically inert precursors that must be 
activated by proteolytic cleavage after secretion. This reaction can be catalyzed by a pair 
of specific, membrane bound extracellular endothelin converting enzymes or by 
nonspecific tissue proteases. The ET1/EDNRA axis is essential in development, with 
knockout mice for either ET1 or EDNRA displaying a similar phenotype featuring 
multiple defects of the craniofacial skeleton and cardiac outflow tract. Prostate and breast 
cancers sometimes display osteoblastic metastases driven by high tumor cell expression 
of ET1. ET1-driven osteosclerosis may also occur in the setting of myelofibrosis. 
Osteoblasts express ET1, EDNRA, and ECE1, and therefore are capable of autocrine ET 
signaling. Searches for genes that mediate individual differences in bone biomechanical 
performance have identified the gene encoding ECE1 as a candidate. Mechanistic studies 
in vitro show that ET signaling in osteoblasts increases matrix synthesis and 
mineralization and derepresses WNT signaling, acting in part via the micro-RNA miR 
126-3p.
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Figure 1. Schematic representation of endothelin synthesis, secretion, and receptor binding
The horizontal line represents the cell membrane, with events above the line occurring 
intracellularly and those below the line occurring extracellularly. Both the ET receptors and 
the ECEs are membrane bound, but their ligand binding/catalytic sites are extracellular. ETA 
represents the A type endothelin receptor, encoded by EDNRA in humans and Ednra in 
mice. ETb represents the B type endothelin receptor, encoded by EDNRB in humans and 
Ednrb in mice. All 3 endothelins are initially synthesized as pre-propeptides, encoded by 
EDN1, EDN2, and EDN3 in humans and Edn1, Edn2, and Edn3 in mice. They are processed 
to the respective big ETs by furin-like proteases prior to secretion. The big ETs are further 
processed to the mature, biologically active ETs by the ECEs or other extracellular 
proteases. B type receptors in endothelial cells promote NO synthesis, cell survival, and ET 
clearance. Both A type and B type receptors promote smooth muscle cell contraction and 
collagen synthesis by fibroblasts.
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Figure 2. Schematic representation of autocrine and paracrine ET1 signaling
In blood vessels, the balance of autocrine and paracrine signaling is important in 
determining the biological response to ET signaling. Big ET1 is secreted by endothelial 
cells. It can be processed to mature ET1 by membrane-bound ECE1 by the endothelial cells 
and signal in an autocrine fashion via either A type or B type receptors on the endothelial 
cells. These cells express predominantly B type receptor, thus favoring vasodilatory 
responses. Alternatively, mature ET1 (21 amino acids) or big ET1 (38 amino acids) can 
diffuse in the extracellular space. Big ET1 can be activated by other tissue proteases and can 
signal via ET receptors located on smooth muscle cells, fibroblasts, or other cells present in 
the vessel wall or perivascular space. Activation of these cell types by ET1 promotes 
vasoconstriction and thickening/stiffening of the media. The activity of ECE1 can alter the 
balance of autocrine v paracrine ET1 signaling.
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Table 1
Genes and Protein Abbreviations
Protein Human Gene Mouse Gene
Endothelin 1 ET1 EDN1 Edn1
Endothelin 2 ET2 EDN2 Edn2
Endothelin 3 ET3 EDN3 Edn3
Endothelin A Type Receptor EDNRA EDNRA Ednra
Endothelin B Type Receptor EDNRB EDNRB Ednrb
Endothelin Converting Enzyme 1 ECE1 ECE1 Ece1
Endothelin Converting Enzyme 2 ECE2 ECE2 Ece2
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